Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study

The Lancet Oncology

Volumn 14, Issue 8, 2013, Pages 733-740

  Robert, Caroline ^a   Dummer, Reinhard ^b   Gutzmer, Ralf ^c   Lorigan, Paul ^d   Kim, Kevin B ^e   Nyakas, Marta ^f   Arance, Ana ^g   Liszkay, Gabriella ^h   Schadendorf, Dirk ⁱ   Cantarini, Mireille ^j   Spencer, Stuart ^j   Middleton, Mark R ^k  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g HOSPITAL CLÍNIC   (Spain)

^h NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j ASTRAZENECA   (United Kingdom)

^k CHURCHILL HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; DACARBAZINE; FUROSEMIDE; IPILIMUMAB; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PLACEBO; RAMIPRIL; SELUMETINIB; VEMURAFENIB;

ABDOMINAL PAIN; ACNE; ADULT; AGED; APPETITE; ARTICLE; ASTHENIA; BACKACHE; BLEEDING TENDENCY; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; ERYSIPELAS; FATIGUE; FEMALE; FLUID RETENTION; FOLLICULITIS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERKERATOSIS; HYPERTENSION; INTENTION TO TREAT ANALYSIS; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAIL INFECTION; NAUSEA; NEUTROPENIA; OSCILLOPSIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETINA VEIN OCCLUSION; RETINOPATHY; SIDE EFFECT; SKIN CARCINOMA; SKIN DISEASE; SKIN INFECTION; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VISUAL ACUITY; VISUAL DISORDER; VITREOUS FLOATERS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BRAZIL; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASMS, UNKNOWN PRIMARY; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84879717023     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70237-7     Document Type: Article

References (30)

1. Lee ML, Tomsu K, Von Eschen KB Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res 2000, 10:81-92.
2. GLOBOCAN 2008 International Agency for Reseach on Cancer, (accessed Jan 22, 2013). http://globocan.iarc.fr/.
3. Zelboraf summary of product characteristics European Medicines Agency, (accessed Nov 13, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002409/WC500124317.pdf.
4. Yervoy summary of product characteristics European Medicines Agency, (accessed Nov 13, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf.
5. Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology 2012, 44:357-359.
6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
7. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011, 17:989-1000.
8. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007, 6:2209-2219.
9. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256.
10. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
11. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007, 13:1576-1583.
12. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008, 26:2139-2146.
13. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012, 18:555-567.
14. Haass NK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008, 14:230-239.
15. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14:38-47.
16. Holt SV, Logie A, Odedra R, et al. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer 2012, 106:858-866.
17. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989, 17:2503-2516.
18. Ellis S, Carroll KJ, Pemberton K Analysis of duration of response in oncology trials. Contemp Clin Trials 2008, 29:456-465.
19. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013, 31:482-489.
20. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
21. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
22. Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:773-781.
23. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
24. Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:2450-2457.
25. Schad K, Baumann CK, Zipser MC, et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010, 16:1058-1064.
26. Middleton MR, Collins L, Gupta A, et al. DOC-MEK: a double blind randomised phase 2 trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. Pigment Cell Melanoma Res 2012, 25:874.
27. Sullivan RJ, Flaherty KT Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013, 49:1297-1304.
28. Dummer R, Flaherty KT Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 2012, 24:150-154.
29. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
30. Atefi M, von Euw E, Attar N, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011, 6:e28973.